Insider BuyALDX· · June 5, 2026, 8:19 PM UTC
Aldeyra CEO Todd Brady buys 250,000 shares of ALDX
A founder-CEO adds a quarter-million shares on the open market.
Todd Brady, president and CEO of Aldeyra Therapeutics, disclosed an open-market purchase of 250,000 ALDX shares, scoring a 68. For a clinical-stage biotech, a founder-CEO buying at this size is a high-signal event worth reading before the next catalyst.
Reporting insider: Brady Todd C · President and CEO · discretionary, open-market
The filing, structured
| Security | Date | Type | Shares | Price | Owned after | Holding |
|---|---|---|---|---|---|---|
| Common Stock | 2026-06-03 | Open-market purchase | +250K | $1.67 | 1.72M | Direct |
FAQ
- What insider transaction did Aldeyra Therapeutics, Inc. (ALDX) report?
- Todd Brady, president and CEO of Aldeyra Therapeutics, disclosed an open-market purchase of 250,000 ALDX shares, scoring a 68. For a clinical-stage biotech, a founder-CEO buying at this size is a high-signal event worth reading before the next catalyst.
- Who made the purchase at $ALDX?
- Brady Todd C, President and CEO, is the reporting insider on this Form 4, a purchase of about $418K.
- Was the $ALDX trade an open-market transaction or a 10b5-1 plan?
- The trade was a discretionary, open-market transaction — not executed under a pre-arranged 10b5-1 plan.
- What is the DEHY Score for this $ALDX filing?
- This filing scored 68 out of 100 on the DEHY Score, a 0–100 triage signal for how much analyst attention a filing warrants — not a price prediction.
Structured from public SEC data within seconds of filing. The DEHY Score is a 0–100 triage signal, not investment advice or a price prediction. See methodology.